Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics
MDGL Price/Volume Stats
| Current price | $194.38 | 52-week high | $322.67 |
| Prev. close | $204.65 | 52-week low | $119.76 |
| Day low | $190.22 | Volume | 707,100 |
| Day high | $200.97 | Avg. volume | 530,471 |
| 50-day MA | $242.88 | Dividend yield | N/A |
| 200-day MA | $201.70 | Market Cap | 3.87B |
MDGL Stock Price Chart Interactive Chart >
Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.
Latest MDGL News From Around the Web
Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to thirty-two new employees with a grant date of December 19, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company's 2023 Inducement Plan. The equity awards were approved in |
Senior VP Robert Waltermire Sells 4,000 Shares of Madrigal Pharmaceuticals Inc (MDGL)In a recent transaction on December 15, 2023, Robert Waltermire, Senior Vice President and Chief of Pharmaceutical Development at Madrigal Pharmaceuticals Inc, sold 4,000 shares of the company's stock. |
11 Stocks Insiders and Billionaires Are Crazy AboutIn this article, we will take a detailed look at the 11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled One Up on Wall Street, Peter Lynch talks about how average investors miss out on opportunities by […] |
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To ProfitMadrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) is possibly approaching a major achievement in its business, so we would... |
Insider Sell Alert: Senior VP Robert Waltermire Sells 3,800 Shares of Madrigal Pharmaceuticals IncMadrigal Pharmaceuticals Inc (NASDAQ:MDGL) has recently witnessed a significant insider sell that has caught the attention of investors and market analysts. |
MDGL Price Returns
| 1-mo | -21.50% |
| 3-mo | -13.98% |
| 6-mo | 61.45% |
| 1-year | -36.74% |
| 3-year | 46.48% |
| 5-year | 75.85% |
| YTD | -15.99% |
| 2023 | -20.28% |
| 2022 | 242.52% |
| 2021 | -23.77% |
| 2020 | 22.02% |
| 2019 | -19.17% |
Loading social stream, please wait...